Sort by
Refine Your Search
-
. By focusing on unique cell-specific receptors, outcomes will inform the development of targeted drug delivery strategies utilizing RNA therapeutics. This research will contribute to a deeper
-
with different diseases in diverse populations and to identify potential therapeutic targets. This is an exciting opportunity to contribute to a programme of research that assess the causal relevance
-
We are seeking a Research Assistant for a project testing the ability of phage to target bacteria carrying plasmids associated with antibiotic resistance genes. Many of the most important antibiotic
-
Postdoctoral Researcher to contribute to our pioneering work focused on enhancing the efficacy of radiotherapy in cancer treatment. Our research aims to develop targeted strategies that selectively increase
-
the effect of target manipulation. You will use reverse genetics to deplete the components from both plant and pathogen to demonstrate their importance in pathogen virulence and plant immunity. We seek
-
of progression to secondary acute myelogenous leukaemia (sAML). You will take a lead on developing data analysis approaches to search for targetable genetic, epigenetic, or epitranscriptomic mechanisms
-
work is to identify new therapeutic targets that can inform drug development for ALS/FTD. Laboratory work will involve differentiations of human iPSCs to motor neurons, developing microfluidic and
-
candidate will be a member of a large multi-disciplinary team working on UPLiFT’s Physics work package (others include the development of IFE lasers and implosion targets). At plasma conditions such as those
-
to target specific transcription factors (iii) use of high content imaging and AI to phenotype these cultures (iii) use of bulk and single-cell RNAseq to characterise the transcriptional profile of each cell
-
. The project involves the discovery of medicinal chemistry optimisation of small molecule modulators of metabolic function and new target discovery using human cellular models. The post is funded by NovoNordisk